Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR339658 (Vatelizumab) in Moderate to Severe Ulcerative Colitis
2012-002013-19Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vatelizumab in autoimmune colitis, sponsored by Sanofi. Started Feb 2013; status: terminated.
02
Drugs
vatelizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2012-002013-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002013-19.